Subcutaneous and systemic injection of Flt3L has proven to stimulate mobilization of different subsets of DCs to the peripheral blood of both healthy donors and patients with melanoma or colon cancer (157, 158). Here, FLT3LG is linked to malignant colon neoplasm.